461 related articles for article (PubMed ID: 26580554)
1. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Grabarska A; Gumbarewicz E; Dmoszynska-Graniczka M; Polberg K; Stepulak A
PLoS One; 2015; 10(11):e0143013. PubMed ID: 26580554
[TBL] [Abstract][Full Text] [Related]
2. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
3. Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis.
Jarząb A; Łuszczki JJ; Guz M; Gumbarewicz E; Polberg K; Stepulak A
Anticancer Res; 2017 Mar; 37(3):1067-1074. PubMed ID: 28314266
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together.
Wawruszak A; Luszczki J; Halasa M; Okon E; Landor S; Sahlgren C; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068438
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.
Ong PS; Wang XQ; Lin HS; Chan SY; Ho PC
Int J Oncol; 2012 May; 40(5):1705-13. PubMed ID: 22328352
[TBL] [Abstract][Full Text] [Related]
6. Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines.
Gumbarewicz E; Luszczki JJ; Wawruszak A; Dmoszynska-Graniczka M; Grabarska AJ; Jarząb AM; Polberg K; Stepulak A
Am J Cancer Res; 2016; 6(12):2831-2845. PubMed ID: 28042503
[TBL] [Abstract][Full Text] [Related]
7. Antagonistic Interaction between Histone Deacetylase Inhibitor: Cambinol and Cisplatin-An Isobolographic Analysis in Breast Cancer In Vitro Models.
Hałasa M; Łuszczki JJ; Dmoszyńska-Graniczka M; Baran M; Okoń E; Stepulak A; Wawruszak A
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445277
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Suzuki M; Endo M; Shinohara F; Echigo S; Rikiishi H
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1115-22. PubMed ID: 19280190
[TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
Feng X; Han H; Zou D; Zhou J; Zhou W
Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
[TBL] [Abstract][Full Text] [Related]
12. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines.
Asgar MA; Senawong G; Sripa B; Senawong T
Int J Oncol; 2016 Jan; 48(1):409-20. PubMed ID: 26575528
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.
Zhou W; Feng X; Han Han ; Guo S; Wang G
Sci Rep; 2016 Jun; 6():28004. PubMed ID: 27292433
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
18. Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells.
Wawruszak A; Okon E; Telejko I; Czerwonka A; Luszczki J
Pharmacol Rep; 2022 Oct; 74(5):1011-1024. PubMed ID: 35900723
[TBL] [Abstract][Full Text] [Related]
19. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
Huang L; Pardee AB
Mol Med; 2000 Oct; 6(10):849-66. PubMed ID: 11126200
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
